Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced positive Phase 1 data for TNX-4800, a long-acting monoclonal antibody targeting Borrelia burgdorferi, the bacterium that causes Lyme disease. The single-dose subcutaneous therapy demonstrated rapid absorption, sustained protective levels for at least four months, and a favorable safety profile in healthy subjects. These results position TNX-4800 as a potential preventative option for Lyme disease, particularly for individuals in endemic areas.
The company plans to initiate an adaptive Phase 2 field study in the first half of 2027, pending FDA clearance, to evaluate the protection afforded by TNX-4800 in at-risk populations. Lyme disease affects hundreds of thousands of people annually in the United States, and current prevention methods are limited to tick avoidance and post-exposure prophylaxis. A long-acting monoclonal antibody could offer a convenient and effective alternative.
Tonix is a fully-integrated, commercial-stage biotechnology company with a focus on central nervous system (CNS) and immunology treatments. Its recently approved flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. The company's CNS commercial infrastructure supports its marketed products, including Zembrace® SymTouch® and Tosymra® for acute migraine. Tonix is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
In addition to its CNS portfolio, Tonix is advancing immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The positive Phase 1 data for TNX-4800 marks a significant step forward in Lyme disease prevention. If successful in Phase 2, the therapy could provide a much-needed tool to reduce the burden of this debilitating disease. The full press release is available at https://ibn.fm/fCumP. For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP.
